Mayo Clinic Evidence-Based Practice Center, Rochester, MN, USA.
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
J Natl Cancer Inst. 2023 Sep 7;115(9):1011-1019. doi: 10.1093/jnci/djad100.
Early-stage breast cancer is among the most common cancer diagnoses. Adjuvant radiotherapy is an essential component of breast-conserving therapy, and several options exist for tailoring its extent and duration. This study assesses the comparative effectiveness of partial-breast irradiation (PBI) compared with whole-breast irradiation (WBI).
A systematic review was completed to identify relevant randomized clinical trials and comparative observational studies. Independent reviewers working in pairs selected studies and extracted data. Randomized trial results were pooled using a random effects model. Prespecified main outcomes were ipsilateral breast recurrence (IBR), cosmesis, and adverse events (AEs).
Fourteen randomized clinical trials and 6 comparative observational studies with 17 234 patients evaluated the comparative effectiveness of PBI. PBI was not statistically significantly different from WBI for IBR at 5 years (RR = 1.34, 95% CI = 0.83 to 2.18; high strength of evidence [SOE]) and 10 years (RR = 1.29, 95% CI = 0.87 to 1.91; high SOE). Evidence for cosmetic outcomes was insufficient. Statistically significantly fewer acute AEs were reported with PBI compared with WBI, with no statistically significant difference in late AEs. Data from subgroups according to patient, tumor, and treatment characteristics were insufficient. Intraoperative radiotherapy was associated with higher IBR at 5, 10, and over than 10 years (high SOE) compared with WBI.
Ipsilateral breast recurrence was not statistically significantly different between PBI and WBI. Acute AEs were less frequent with PBI. This evidence supports the effectiveness of PBI among selected patients with early-stage, favorable-risk breast cancer who are similar to those represented in the included studies.
早期乳腺癌是最常见的癌症诊断之一。辅助放疗是保乳治疗的重要组成部分,存在多种方法可以调整其范围和持续时间。本研究评估了部分乳房照射(PBI)与全乳房照射(WBI)的比较效果。
进行了系统评价,以确定相关的随机临床试验和比较观察性研究。独立的评审员成对工作,选择研究并提取数据。使用随机效应模型对随机试验结果进行了汇总。预设的主要结局是同侧乳房复发(IBR)、美容效果和不良事件(AEs)。
有 14 项随机临床试验和 6 项比较观察性研究,涉及 17234 名患者,评估了 PBI 的比较效果。在 5 年(RR=1.34,95%CI=0.83 至 2.18;高证据强度[SOE])和 10 年(RR=1.29,95%CI=0.87 至 1.91;高 SOE)时,PBI 与 WBI 相比,IBR 无统计学差异。美容结局的证据不足。与 WBI 相比,PBI 报告的急性 AE 明显减少,但晚期 AE 无统计学差异。根据患者、肿瘤和治疗特征的亚组数据不足。与 WBI 相比,术中放疗与 5 年、10 年和 10 年以上的 IBR 更高(高 SOE)相关。
PBI 与 WBI 之间的 IBR 无统计学差异。PBI 的急性 AE 发生率较低。该证据支持在与纳入研究相似的早期、低危乳腺癌患者中选择 PBI 的有效性。